Valanx BiotechAntibody drug conjugatesVienna’s VALANX secures €3 million to push preclinical ADC programme in breast cancerVALANX Biotech has raised €3 million in a Series A funding round to advance an antibody-drug conjugate (ADC) targeting LIV-1 for triple-negative breast cancer. The developments are currently still … more ➔
M&AEnodia strikes up to $127m deal for Kezar’s preclinical protein degradation assetsParis-based Enodia Therapeutics announced the acquisition of preclinical assets from San Francisco-based Kezar Life Sciences’ pipeline. Both companies are developers of small molecules that target … more ➔
Evotec SEEvotecHamburg CRO Evotec to cut costs further and reduce workforce by 800Cost-cutting measures sometimes arrive wrapped in reassuring language. “Horizon” is the name Evotec SE has given to the next stage of its restructuring programme, which will affect additional sites … more ➔
Unsplash+Drug developmentIpsen withdraws cancer drug following safety concernsIpsen has announced the immediate withdrawal of its cancer drug Tazverik across all indications after serious safety issues emerged in an ongoing Phase III trial. more ➔
Marcus Krauss - stock.adobe.com BioNTechA new departure: BioNTech’s founders step aside – Sahin and Türeci in new ventureThe Mainz-based biotech company BioNTech is facing a historic leadership change as the minds behind the COVID-19 vaccine prepare for a fresh start. Uğur Şahin and Özlem Türeci plan to focus entirely … more ➔
RocheBreast CancerRoche breast cancer drug falls short of expectations (for now)Setback after earlier optimism: the Roche drug giredestrant has delivered mixed clinical data. Several clinical trials had suggested the drug could play an important role in the treatment of hormone-dependent … more ➔
ObesityRoche and Zealand’s obesity contender clears phase 2, but investors were looking for moreRoche and Zealand Pharma have delivered a clinically positive phase 2 readout for petrelintide, their amylin-based obesity drug, but the market reaction made clear that “positive” is no longer enough … more ➔
M&AAlfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decisionItalian drugmaker Alfasigma has struck a licensing deal to take over global rights to linerixibat, GSK’s late-stage candidate for cholestatic pruritus in primary biliary cholangitis (PBC), in a transaction … more ➔
Unsplash+M&AServier buys Day One for $2.5bn to bolster its rare cancer pipelineFrench pharma giant Servier is spending US$2.5bn to snap up Day One Biopharmaceuticals, gaining a key approved drug for difficult childhood brain tumours along with several promising pipeline candid … more ➔
Startupskyron.bio teams up with Servier to test “precision glycosylation” as a new lever for antibody performanceParis-based kyron.bio has signed a strategic partnership with French pharma group Servier to glycoengineer an antibody selected by Servier. This agreement marks an early proof-of-concept deal designed … more ➔
Valanx Biotech
Evotec SE
Unsplash+
Marcus Krauss - stock.adobe.com 
Roche
Unsplash+